It is a broadly described annual report of The IBN SINA Pharmaceutical Industry Limited in the year of 2017. The IPI had made a significant contribution in the year 2016-17 towards the National Exchequer by paying Tk. 730,768,294 as Income Tax and VAT. This is equivalent to 18.23% of the sales in the year under review. In the year 2016-17 EPS stood Tk. 9.06 which was Tk. 7.85 in 2015-16. In the year under review Net Asset Value per share is Tk. 42.79 in 2016-17 which was Tk. 33.67 in 2015-16 and in the year 2016-17 Net Asset Value Tk. 110,49,63,231 which was Tk. 86,94,31,628 over the last corresponding year. During the year under review, 14.85% Sales growth was achieved. In the year 2016-17 overall sales achievement stood at Tk. 4009.15 million which was Tk. 3,490.80 million in the last year. Profit after tax for the financial year 2017 Taka. 233,859,346 million.
After evaluating the Financial Statements for the year 2016-17 of the Company, the Board of Directors proposed a stock dividend of @ 10% and the cash dividend of @ 25% as against per share of Tk. 10 each. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.
More Annual Report of The IBN SINA Pharmaceutical Industry Limited:
- Annual Report 2010 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2011 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2012 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2013 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2014 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2017 of The IBN SINA Pharmaceutical Industry Limited
